Stock analysts expect Harrow Health, Inc. (NASDAQ:HROW – Get Rating) to report earnings of ($0.04) per share for the current quarter, reports Zacks Investment Research. Zero analysts released earnings estimates for Harrow Health. Harrow Health reported earnings per share of $0.01 in the same quarter last year, indicating a negative 500% year-over-year growth rate. The company is expected to announce its next earnings report after the market closes on Monday, January 1.
According to Zacks, analysts expect Harrow Health to report annual earnings of $0.04 per share for the current year, with EPS estimates ranging from ($0.08) to $0.15. For the next fiscal year, analysts expect the company to post earnings of $0.36 per share, with EPS estimates ranging from $0.31 to $0.40. Zacks Investment Research’s EPS calculations are an average average based on a survey of sell-side research companies that cover Harrow Health.
Harrow Health (NASDAQ:HROW – Get Rating) last reported quarterly results on Thursday, March 10. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.08 per ($0.09). The company posted revenue of $20.19 million for the quarter, versus $21.35 million expected by analysts. Harrow Health had a negative net margin of 24.84% and a positive return on equity of 4.36%. In the same quarter a year earlier, the company posted earnings per share of $0.07.
Separately, Zacks Investment Research downgraded Harrow Health from a “hold” rating to a “strong sell” rating in a Tuesday, March 15 research note.
Separately, major shareholder Opaleye Management Inc. acquired 28,557 shares of the company in a transaction dated Tuesday, April 12. The stock was purchased at an average price of $6.75 per share, with a total value of $192,759.75. Following the purchase, the insider now directly owns 3,165,000 shares of the company, valued at approximately $21,363,750. The purchase was disclosed in a filing with the SEC, accessible via this hyperlink. Insiders hold 16.67% of the shares of the company.
A number of hedge funds and other institutional investors have recently increased or reduced their stakes in the company. Exencial Wealth Advisors LLC acquired a new position in Harrow Health shares in Q3 valued at approximately $190,000. Barclays PLC increased its position in Harrow Health shares by 119.8% during the third quarter. Barclays PLC now owns 5,412 shares in the company valued at $49,000 after acquiring a further 2,950 shares in the last quarter. Geode Capital Management LLC increased its position in Harrow Health by 5.3% in the third quarter. Geode Capital Management LLC now owns 229,852 shares of the company worth $2,089,000 after purchasing an additional 11,635 shares during the period. Wasatch Advisors Inc. acquired a new stake in Harrow Health in the third quarter valued at $5,164,000. Finally, Franklin Resources Inc. acquired a new stake in Harrow Health in the third quarter at a value of $144,000. Hedge funds and other institutional investors hold 43.57% of the company’s shares.
Shares of HROW were down $0.12 during Friday trading hours, hitting $6.76. 197,618 shares were traded, against an average volume of 69,366. The company has a leverage ratio of 6.56, a quick ratio of 5.81 and a current ratio of 6.24. Harrow Health has a 12 month minimum of $6.58 and a 12 month maximum of $12.99. The company has a market capitalization of $182.72 million, a price-earnings ratio of -9.94 and a beta of 0.96. The stock’s 50-day moving average price is $7.29 and its two-hundred-day moving average price is $8.57.
Harrow Health Company Profile (Get an assessment)
Harrow Health, Inc. operates as an ophthalmology-focused healthcare company. The Company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of postoperative inflammation. The Company also has interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company focused on developing and commercializing therapies for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of proprietary non-intravenous, sedation and anesthesia therapeutic products for human medical procedures in inpatient, outpatient and office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company engaged in the development and commercialization of pharmaceutical products.
Get a free copy of Zacks’ research report on Harrow Health (HROW)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for Harrow Health Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Harrow Health and related companies with MarketBeat.com’s FREE daily newsletter.